Tenet Healthcare Corporation
NYSE:THCMedical - Care Facilities
-$5.06 today
- Market cap
- $21.60B
- Beta
- 1.28
- P/E (TTM)
- 9.1
- EPS (TTM)
- $19.62
Volume 1.57M
Average 1.41M
THC Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Tenet Healthcare CorporationNYSE: THC
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin narrows to 18.2%
Gross margin was 18.2% in Q2 FY2026, down 64.1 pp from a year earlier. On a trailing-twelve-month basis it was 26.9%, down 34.6 pp year over year. Over 3 fiscal years it widened by 45.5 pp.
Context
- Gross margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 82.3%
- Year-over-year change
- +42.5pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 82.3% | +42.5pp |
| FY2024 | 2024-12-31 | 39.7% | +1.7pp |
| FY2023 | 2023-12-31 | 38.0% | +1.2pp |
| FY2022 | 2022-12-31 | 36.8% | -0.5pp |
| FY2021 | 2021-12-31 | 37.3% | — |
Gross Margin vs competitors
How THC compares with its peers on the latest reported figures
- THC's LTM Jun 2026 gross margin of 26.9% is the 6th highest of the 7 companies compared; the peer median is 39.8%.
- Its year-over-year change of -34.6 pp is the lowest of 7, against a peer median of -1.1 pp.
- Over three fiscal years its change of +45.5 pp compares with a peer median of +2.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 90.7% | +0.5 pp | +1.4 pp | |
| LTM Mar 2026 | 53.7% | +11.9 pp | -31.5 pp | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | 49.7% | -26.6 pp | +16.2 pp |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | 29.9% | +1.5 pp | +4.7 pp |
| LTM Jun 2026 | 28.4% | -12.5 pp | +3.0 pp | |
| LTM Jun 2026 | 26.9% | -34.6 pp | +45.5 pp | |
| LTM Sep 2026 | 21.1% | -2.8 pp | +0.5 pp | |
| Peer median (excluding THC) | 39.8% | -1.1 pp | +2.2 pp | |
Competitors are the stored peer set for THC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.49B | 19.17B | 20.55B | 20.67B | 21.31B |
| Cost of Revenue | 12.22B | 12.13B | 12.74B | 12.46B | 3.78B |
| Gross Profit | 7.27B | 7.05B | 7.81B | 8.21B | 17.53B |
| Gross Margin | 37.3% | 36.8% | 38.0% | 39.7% | 82.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 412M | 412M | 418M | 8.8B | 8.71B |
| Operating Expenses | 4.4B | 4.72B | 5.3B | 2.25B | 14.09B |
| Depreciation & Amortization | 855M | 841M | 870M | 818M | 863M |
| EBITDA | 3.67B | 3.08B | 3.39B | 6.89B | 4.48B |
| EBITDA Margin | 18.8% | 16.0% | 16.5% | 33.4% | 21.0% |
| Operating Income | 2.87B | 2.33B | 2.51B | 5.96B | 3.44B |
| Operating Margin | 14.7% | 12.2% | 12.2% | 28.8% | 16.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 923M | 890M | 901M | 826M | 821M |
| Other Income / Expenses | (983M) | (988M) | (893M) | (708M) | (639M) |
| Income Before Tax | 1.89B | 1.35B | 1.62B | 5.25B | 2.8B |
| Pre-Tax Margin | 9.7% | 7.0% | 7.9% | 25.4% | 13.1% |
| Income Tax Expense | 411M | 344M | 306M | 1.18B | 433M |
| Net Income | 914M | 411M | 611M | 3.2B | 1.41B |
| Net Margin | 4.7% | 2.1% | 3.0% | 15.5% | 6.6% |
| EPS (Basic) | 8.55 | 3.84 | 6.01 | 33.02 | 15.61 |
| EPS (Diluted) | 8.42 | 3.79 | 5.71 | 32.70 | 15.49 |
| Weighted Avg Shares | 106.83M | 106.93M | 101.64M | 96.9M | 90.15M |
| Weighted Avg Shares (Diluted) | 108.57M | 110.52M | 104.8M | 97.88M | 90.83M |
Tenet Healthcare Corporation
NYSE:THC
Intrinsic Alpha fair value
Locked
Current Price
$271.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.